Amvuttra
E446848
Amvuttra is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Amvuttra canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4492416 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Amvuttra Context triple: [Alnylam Pharmaceuticals, develops, Amvuttra]
-
A.
Amarar
Amarar is the native name used by the Beja people to refer to themselves or their community.
-
B.
Wonokitri
Wonokitri is a village in East Java, Indonesia, known as a gateway settlement for visitors heading to the Mount Bromo area.
-
C.
Shivta
Shivta is an ancient Nabatean and Byzantine desert city in Israel, known for its remarkably well-preserved ruins and role along historic trade routes.
-
D.
Upangas
Upangas are a group of secondary Jain scriptures that elaborate and supplement the teachings found in the primary Agamas.
-
E.
Huvishka
Huvishka was a prominent Kushan emperor of the 2nd century CE, known for his extensive coinage and role in consolidating the empire’s power and cultural diversity across Central and South Asia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Amvuttra Target entity description: Amvuttra is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
-
A.
Amarar
Amarar is the native name used by the Beja people to refer to themselves or their community.
-
B.
Wonokitri
Wonokitri is a village in East Java, Indonesia, known as a gateway settlement for visitors heading to the Mount Bromo area.
-
C.
Shivta
Shivta is an ancient Nabatean and Byzantine desert city in Israel, known for its remarkably well-preserved ruins and role along historic trade routes.
-
D.
Upangas
Upangas are a group of secondary Jain scriptures that elaborate and supplement the teachings found in the primary Agamas.
-
E.
Huvishka
Huvishka was a prominent Kushan emperor of the 2nd century CE, known for his extensive coinage and role in consolidating the empire’s power and cultural diversity across Central and South Asia.
- F. None of above. chosen
Statements (44)
| Predicate | Object |
|---|---|
| instanceOf |
RNA interference therapeutic
ⓘ
drug ⓘ small interfering RNA ⓘ transthyretin-directed therapy ⓘ |
| approvalYear | 2022 ⓘ |
| belongsToPlatform | RNAi therapeutics platform ⓘ |
| countryApprovedIn |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| developer | Alnylam Pharmaceuticals ⓘ |
| dosingFrequency | once every three months ⓘ |
| effect | reduces production of transthyretin protein ⓘ |
| hasATCClass | N07XX ⓘ |
| hasDosingInterval | 12 weeks ⓘ |
| hasDrugClass |
RNAi therapeutic
ⓘ
gene silencing agent ⓘ transthyretin synthesis inhibitor ⓘ |
| hasEffectOn | polyneuropathy progression in hATTR amyloidosis ⓘ |
| hasFormulation | solution for injection ⓘ |
| hasGenericName | vutrisiran ⓘ |
| hasInternationalNonproprietaryName |
vutrisiran
ⓘ
linked to:
AMVUTTRA (vutrisiran)
|
| hasMolecularTarget | transthyretin ⓘ |
| hasPharmacologicalAction | gene expression inhibitor ⓘ |
| hasRegulatoryStatus |
EMA approved
ⓘ
FDA approved ⓘ |
| indication | treatment of adults with hereditary transthyretin-mediated amyloidosis ⓘ |
| isAdministered | subcutaneously ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isFirstInClass | subcutaneous RNAi therapeutic for hATTR polyneuropathy ⓘ |
| isIndicatedFor | adult patients ⓘ |
| isLongActing | true ⓘ |
| isNotIndicatedFor | pediatric patients ⓘ |
| isProprietaryNameOf |
vutrisiran
ⓘ
linked to:
AMVUTTRA (vutrisiran)
|
| isUsedFor | disease-modifying treatment of hATTR amyloidosis ⓘ |
| marketingAuthorizationHolder | Alnylam Pharmaceuticals ⓘ |
| mechanismOfAction | RNA interference–mediated degradation of transthyretin mRNA ⓘ |
| reduces |
amyloidogenic transthyretin variants
ⓘ
serum transthyretin levels ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| targets | transthyretin mRNA ⓘ |
| therapeuticArea |
amyloidosis
ⓘ
neurology ⓘ rare diseases ⓘ |
| treats |
hereditary transthyretin-mediated amyloidosis
ⓘ
polyneuropathy of hereditary transthyretin-mediated amyloidosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Amvuttra Description of subject: Amvuttra is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.